Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03771612 · ClinicalTrials.gov registry record · Early Phase 1
Inflammation and Daily Life Study
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 144
- Enrollment target
NCT03771612 is a Early Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 144 participants.
The verdict
NCT03771612, a Early Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 144 participants
- Enrollment target
Study Summary
UCLA researchers looking for healthy individuals (age 45-60) to participate in a study investigating whether an anti-inflammatory medication can impact daily life experiences. Everyday for two weeks, participants will take either an anti-inflammatory medication (naproxen) twice daily, or a placebo pill twice daily. Participants will also answer daily questions during the 2-week period. Participants will also fill out questionnaires and complete a few tasks on the computer: once prior to the 2-week period and once immediately after the 2-week period, both during online study sessions.
Interventions
- DRUG Placebos
- DRUG Naproxen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2022-02-09 |
| Est. Completion | 2024-06-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03771612
The ClinicalTrials.gov registry entry for NCT03771612 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03771612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03771612 about?
NCT03771612 is a clinical study titled "Inflammation and Daily Life Study". UCLA researchers looking for healthy individuals (age 45-60) to participate in a study investigating whether an anti-inflammatory medication can impact daily life experiences. Everyday for two weeks, participants will take either an anti-inflammatory medication (naproxen) twice daily, or a placebo ...
What is the current status of trial NCT03771612?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 144 participants. The study started on 2022-02-09. Estimated completion is 2024-06-21.
What interventions are being tested in trial NCT03771612?
The interventions under investigation include: Placebos (DRUG), Naproxen (DRUG).
Who is sponsoring clinical trial NCT03771612?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.